GlassScriptPhysician profile
Ilya M Rozenbaum
NPI 1831240704
$3,179.55
in general payments reported to CMS, 2019-2025
20 companies · $400 in 2025
The $400 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $390 · 2020: $27.80 · 2021: $133 · 2022: $1,570 · 2023: $304 · 2024: $354 · 2025: $400.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,058.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,058.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,235.30 | 2022-2025 | Qulipta, Ubrelvy |
| Alcon Vision LLC | $414.60 | 2022-2025 | Hydrus Microstent, Clareon, Tryptyr |
| New World Medical,INC. | $314.60 | 2022 | |
| Rxsight INC | $244.23 | 2023-2024 | Rxsight Injector Cartridge, Rxsight Contact Lens, Rxsight Light Delivery Device (Ldd) |
| Sight Sciences, INC. | $225.10 | 2019-2025 | Omni Surgical System, Sion Surgical Instrument |
| Ivantis, INC | $129.31 | 2019 | |
| Bausch & Lomb Americas INC. | $107.22 | 2024 | Envista Mx60 Iol, Envista Aspire Iol |
| Eyepoint US, INC. | $92.54 | 2019 | |
| Oyster Point Pharma, INC. | $91.98 | 2022 | |
| Biotissue Holdings INC. | $81.17 | 2024-2025 | |
| Sun Pharmaceutical Industries INC. | $74.51 | 2019-2023 | Cequa |
| Shire North American Group INC | $29.74 | 2019 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $28.53 | 2019 | |
| Novartis Pharmaceuticals Corporation | $27.93 | 2019-2020 | |
| Genentech USA, INC. | $25.76 | 2024 | Vabysmo |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Omeros Corporation | $18.61 | 2019 | |
| Harrow Eye, LLC | $17.00 | 2024 | Vevye |
| Allergan, INC. | $11.25 | 2019 | |
| Quidel Corporation | $10.17 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ilya Rozenbaum listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.